In a phase II study involving 51 patients with pilonidal sinus (PNS), RD2 Ver.02 demonstrated significant results. Three months post-treatment, 82.4% achieved primary healing, increasing to 90.2% and 82.4% at six and twelve months, respectively. Recurrence occurred in 11.8% of patients within a year, while five adverse events were reported, none severe. Thus, RD2 Ver.02 appears to be a safe and effective option when used alongside a minimally invasive procedure.
Clinical Trial, Phase II by Ram E, Zager Y (…) Horesh N et 4 al. in Tech Coloproctol
© 2024. Springer Nature Switzerland AG.